STR001 as a Novel Treatment for Hearing Loss - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

18117.1 PFLS-LS

Project title

STR001 as a Novel Treatment for Hearing Loss

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	STR001 as a Novel Treatment for Hearing Loss
Short description (English)	STR001 as a Novel Treatment for Hearing Loss
Abstract (German)	STR001 is a drug that Strekin aims to develop for the treatment of hearing loss. Damage to sensory hair cells in the inner ear is a primary cause of sensorineural hearing loss. The proposed drug has been shown to activate a target that favorably affects pathways implicated in hearing health. In this project, we conduct translational preclinical research of STR001 to enable fast entry into clinical development and value creation.
Abstract (English)	STR001 is a drug that Strekin aims to develop for the treatment of hearing loss. Damage to sensory hair cells in the inner ear is a primary cause of sensorineural hearing loss. The proposed drug has been shown to activate a target that favorably affects pathways implicated in hearing health. In this project, we conduct translational preclinical research of STR001 to enable fast entry into clinical development and value creation.